Catalyst Capital Advisors’s Tempest Therapeutics TPST Stock Holding History

Catalyst Capital Advisors’s Portfolio TPST Stock Details TPST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-53	Closed	-$4.46M	–	613
2015 Q2	$4.46M	Buy	53 +17	+47%	+$1.56M	0.52%	76
2015 Q1	$3.63M	Sell	36 -4	-10%	-$533K	0.42%	86
2014 Q4	$5.18M	Sell	40 -1	-2%	-$73.2K	0.61%	51
2014 Q3	$1.98M	Hold	41	–	–	0.25%	92
2014 Q2	$1.09M	Hold	41	–	–	0.18%	146
2014 Q1	$1.06M	Buy	41 +2	+5%	+$56.7K	0.24%	127
2013 Q4	$1.04M	Buy	39 +33	+550%	+$905K	0.34%	103
2013 Q3	$178K	Buy	+6	New	+$213K	0.1%	223

Other funds holding TPST

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Orbis Holdings Hamilton, Bermuda $12.8B AUM 8.29% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Catalyst Capital Advisors's TPST Position: Q3 2015 in Review

Catalyst Capital Advisors sold out of Tempest Therapeutics (TPST) in Q3 2015, closing a stake of 53 shares — an estimated $4.46M sold.

Catalyst Capital Advisors first reported a position in TPST in Q3 2013 and held it in 8 quarters. The position peaked at $5.18M in Q4 2014. 90 funds tracked by Wall St. Rank hold TPST as of Q3 2015.

Catalyst Capital Advisors reported no remaining Tempest Therapeutics position as of Q3 2015 after selling out during the quarter.
Catalyst Capital Advisors sold 53 Tempest Therapeutics shares in Q3 2015, an estimated $4.46M.
Catalyst Capital Advisors first reported a position in Tempest Therapeutics in Q3 2013 and held it in 8 quarters.
Catalyst Capital Advisors's Tempest Therapeutics position peaked at $5.18M in Q4 2014.
90 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q3 2015.

Based on Catalyst Capital Advisors's 13F filing for Q3 2015, filed 12 Nov 2015.